ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the fourth quarter and full year ...
Focus shifted to development of first tri-specific antibody from the CAPTN-3 platform, IM1240, targeting 5T4 tumor-associated ...
This Q3 was the first quarter in over 15 years where organic total revenue and non-GAAP earnings per share both grew at 20% or more in USD. Cloud revenue was at the high end of our guidance, total ...
Fox River Grove residents will have no permit fees for “basic” building projects, as part of a move to lessen resident costs after the village board enacted a 1% sales tax last year. The village ...
LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year-end 2026 Recent amendment to HealthCare Royalty ...
Top-Line Data from Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Expected by Year-End 2026 - - Raised Proceeds of $200 Million in ...
Self-interest describes actions that are intended to result in personal gain. It comes with both pros and cons.
Held Type A meeting with FDA to discuss AMT-130 for Huntington’s disease; Company evaluating Phase III development considerations and plans to ...
Detailed price information for Collegium Pharma (COLL-Q) from The Globe and Mail including charting and trades.
Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...
We have published our annual report for the 2023-24 season, between 1 August 2023 to 31 July 2024. This season marked the final financial year of our 2020-24 Time For Change strategic plan. During ...
El Pollo Loco Holdings, Inc. (Nasdaq: LOCO) today announced financial results for the 14- and 53-week periods ended December 31, 2025. Highlights for the fourth quarter ended December 31, 2025 ...